Michael Barbella, Managing Editor07.14.22
Shimadzu Corporation has debuted the newest version of its Trinias angiography system.
The new Trinias system uses artificial intelligence (AI) deep learning technology to improve the visibility of medical devices while using 40% or more lower1 X-ray dose than previous models. This represents the first time AI has been incorporated into the image processing engine of an angiography system.
The new Trinias system also offers an extensive new feature set to simplify workflow, allowing a more efficient clinical operation in any medical setting. With the launch of a subscription service that ensures software can always be updated to the current version, the new Trinias system offers a sustainable product designed for long-term use.
Angiography systems are used to perform angiographic examinations, where the physician inserts a catheter (small tube) through a blood vessel in the patient's wrist or inguinal region to a specific site (in the heart, head, liver, lungs, etc.) and observes an area of disease or concern, and to perform catheterization procedures, where a therapeutic device is inserted in the patient and used to dilate blood vessels or perform other interventional procedures.
Medical facilities are increasingly operating angiography systems at low radiation levels to reduce X-ray doses, but low radiation levels also lead to X-ray noise that reduces device visibility. To support the low-dose operation of angiography systems by medical facilities and ever-smaller therapeutic devices that reduce the burden on patients, Shimadzu has developed SCORE Opera, a new image processing technology that uses AI to ensure catheterization procedures are safe even at low radiation doses.
The company's new concept is based on three important design principles, and it is developed to provide solutions to the most challenging issues in today's healthcare workplace.
Shimadzu Corporation, founded in 1875 in Kyoto, Japan, and the parent of Shimadzu Medical Systems USA (SMS), is a global provider of medical diagnostic equipment including conventional, interventional and digital X-Ray systems. Shimadzu Medical Systems USA is headquartered in Torrance, Calif., with sales and service offices throughout the United States, the Caribbean, and Canada. Its sales and marketing office is located in Cleveland, Ohio, and has direct operations headquartered in Dallas, and Kenmore, Wash.
Reference
1 Comparison with our conventional system under standard dose ratio (Air Kerma) at 7.5pps and 10pps.
The new Trinias system uses artificial intelligence (AI) deep learning technology to improve the visibility of medical devices while using 40% or more lower1 X-ray dose than previous models. This represents the first time AI has been incorporated into the image processing engine of an angiography system.
The new Trinias system also offers an extensive new feature set to simplify workflow, allowing a more efficient clinical operation in any medical setting. With the launch of a subscription service that ensures software can always be updated to the current version, the new Trinias system offers a sustainable product designed for long-term use.
Angiography systems are used to perform angiographic examinations, where the physician inserts a catheter (small tube) through a blood vessel in the patient's wrist or inguinal region to a specific site (in the heart, head, liver, lungs, etc.) and observes an area of disease or concern, and to perform catheterization procedures, where a therapeutic device is inserted in the patient and used to dilate blood vessels or perform other interventional procedures.
Medical facilities are increasingly operating angiography systems at low radiation levels to reduce X-ray doses, but low radiation levels also lead to X-ray noise that reduces device visibility. To support the low-dose operation of angiography systems by medical facilities and ever-smaller therapeutic devices that reduce the burden on patients, Shimadzu has developed SCORE Opera, a new image processing technology that uses AI to ensure catheterization procedures are safe even at low radiation doses.
The company's new concept is based on three important design principles, and it is developed to provide solutions to the most challenging issues in today's healthcare workplace.
Shimadzu Corporation, founded in 1875 in Kyoto, Japan, and the parent of Shimadzu Medical Systems USA (SMS), is a global provider of medical diagnostic equipment including conventional, interventional and digital X-Ray systems. Shimadzu Medical Systems USA is headquartered in Torrance, Calif., with sales and service offices throughout the United States, the Caribbean, and Canada. Its sales and marketing office is located in Cleveland, Ohio, and has direct operations headquartered in Dallas, and Kenmore, Wash.
Reference
1 Comparison with our conventional system under standard dose ratio (Air Kerma) at 7.5pps and 10pps.